Innoviva Q1 net income $36.5M ($0.58 basic EPS); product sales up 66% YoY to $19.1M; GSK royalties $61.9M

Innoviva, Inc.

2024-Q1 EPS reported $0.46 revenue$77,499,000

Net income $36.5M ($0.58 basic EPS) vs $34.9M ($0.51) in Q1 2023.
Net product sales $19.1M, +66% YoY, driven by XACDURO launch and GIAPREZA growth.
GSK royalty revenue $61.9M, up from $60.3M in Q1 2023.
Repurchased 0.6M shares for $9.7M in Q1 2024; completed $5.3M buyback post-quarter.
Positive Phase 3 zoliflodacin results for uncomplicated gonorrhea; NDA submission expected early 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Innoviva, Inc. reported first quarter ended March 31, 2024 results: net income $36.5 million, or $0.58 basic per share.

Period: first quarter ended March 31, 2024
Net income: $36.5 million, or $0.58 basic per share
Result: reported results

Exact text from the filing

Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-058747

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.